Skip to main content
AMB Express
Fig. 7 | AMB Express

Fig. 7

From: Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia

Fig. 7

Targeting PARP and autophagy elicited synergetic anti-tumor effect in pediatric CML. Patient-derived xenograft (PDX) model was established to evaluate the anti-tumor efficacy of talazoparib and/or chloroquine in CML. Tumor volume was measured once every 3 days. After treatment with talazoparib and/or chloroquine for 21 days, tumor weight was shown as mean ± SD. Each point indicated an independent value from one mouse (n = 5). NS no significance; **P < 0.01

Back to article page